EDAP TMS S.A. Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $79.3M+14.3% YoYTTM through 30 Jun 2026
Net Income -$39MTTM through 30 Jun 2026
Free Cash Flow -$13MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 42.5% |
| EBITDA Margin | -29.8% |
| Operating Margin | -35.0% |
| Net Margin | -49.1% |
Returns
-150.4%ROE
-37.0%ROA
Balance Sheet Health
Debt / Equity1.27x
Current Ratio1.54x
Net Debt$4.2M
Cash & Equivalents$21.5M
Quality Metrics
Altman Z-Score-1.14
Piotroski F-Score4 / 9
FCF Margin-16.4%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $70.5M
Diluted EPS-$1.04TTMFY2025: $-0.78
Dividend
No dividend
Capital Allocation
R&D Spend$9.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| HIFU | $37.4M | +39.0% | View detailsCore HIFU business revenue is expected to grow significantly as the primary driver of overall company performance. |
| Non-Core (ESWL and Distribution) | $33.2M | -27.0% | View detailsExpected to continue to decline as a percentage of total revenue over time. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.